Gyre Therapeutics completes enrollment in Phase 3 trial of Pirfenidone capsules

Gyre Therapeutics (GYRE) announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis. A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis.